Clinical Scorecard: Ocular Surface Disease Treatments in the Pipeline
At a Glance
| Category | Detail |
|---|---|
| Condition | Ocular Surface Disease (OSD) |
| Key Mechanisms | Tear film instability, inflammation, and disruption of ocular surface homeostasis. |
| Target Population | Individuals with dry eye disease (DED), estimated at over 20 million in the U.S. and 350 million globally. |
| Care Setting | Ophthalmology and optometry clinics. |
Key Highlights
- Diverse treatment options including traditional eye drops, nasal sprays, and lacrimal occlusion.
- Emerging therapies targeting inflammation, tear production, and specific conditions like meibomian gland dysfunction.
- Notable candidates in development include reproxalap and AR-15512, targeting novel pathways and improving patient compliance.
Guideline-Based Recommendations
Diagnosis
- Identify the appropriate subtype of ocular surface disease for tailored treatment.
Management
- Utilize a multimodal approach to address symptoms and underlying pathology.
Monitoring & Follow-up
- Regular assessment of tear film stability and ocular surface health.
Risks
- Potential for chronic symptoms and complications if not properly managed.
Patient & Prescribing Data
Patients suffering from chronic dry eye disease and associated ocular surface conditions.
Recent advancements in therapies offer targeted mechanisms to improve outcomes.
Clinical Best Practices
- Tailor therapies to individual patient needs and tolerance.
- Stay updated on emerging treatments and their mechanisms of action.
References
- TFOS DEWS II Definition and Classification Report
- Prevalence of Diagnosed Dry Eye Disease in the United States
- Dry Eye Breakthroughs in the Making
- A review of the first anti-evaporative prescription treatment for dry eye disease
- Aldeyra Therapeutics achieves primary endpoint in phase 3 dry eye disease clinical trial of Reproxalap
- Dry Eye Disease Associated with Meibomian Gland Dysfunction
- Positive Topline Results From Phase 3 COMET Trials of AR-15512
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.